Achillion Pharmaceut (ACHN) 9.14 $ACHN Achillion

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 1:19 AM

Achillion Pharmaceut (ACHN) 9.14 $ACHN

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 9.14 (+0.26)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.14 (+0.26), JAZZ: 139.88 (+1.40), GRFS: 16.92 (+0.27), PBYI: 34.88 (+2.73)

Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 9.14 (+0.26)

Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 9.14 (+0.26)

Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 9.14 (+0.26)

Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 9.14 (+0.26)

Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 9.14 (+0.26), DB: 12.97 (+0.37)

Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 9.14 (+0.26)

First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 9.14 (+0.26)

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 9.14 (+0.26), AVXS: 37.70 (+0.98)

Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu Mar 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
ACHN: 9.14 (+0.26)

Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 122.85 (+0.34), INO: 9.11 (+0.03), ACHN: 9.14 (+0.26), GSK: 43.38 (+0.04), NVS: 82.13 (+0.33), CELGZ: 1.43 (+0.08)

Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 122.85 (+0.34), GILD: 86.55 (+1.08), ACHN: 9.14 (+0.26), BMY: 75.28 (+1.20)

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 9.14 (+0.26)

Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 8:30AM CST
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global Eagle Entertainment, LendingClub and Barracuda Networks
LC: 4.32 (+0.07), OPK: 9.87 (+0.01), ACHN: 9.14 (+0.26), CUDA: 18.43 (+2.92), ENT: 7.10 (+0.45)

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnv8gp/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Paroxysmal Nocturnal Hemoglobinuria Overview - Therapeutics Development - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview - Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies - Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes - Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development - Achillion Pharmaceuticals, Inc. - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Apellis Pharmaceuticals, Inc. - Epirus Biopharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Ra Pharmaceuticals, Inc. - Regenesance BV - The International Biotechnology Center (IBC) Generium For more information visit http://www.researchandmarkets.com/research/nnv8gp/paroxysmal
ACHN: 9.14 (+0.26), ALXN: 124.42 (+1.08), OMER: 11.59 (-0.02), NVS: 82.13 (+0.33)

A Company's First Profit Can Mean Big Profits to Investors
Kevin Matras - Zacks Investment Research - Tue Jan 26, 2:04PM CST
A Company's First Profit Can Mean Big Profits to Investors
LC: 4.32 (+0.07), OPK: 9.87 (+0.01), ACHN: 9.14 (+0.26), CUDA: 18.43 (+2.92), ENT: 7.10 (+0.45)

The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals
INO: 9.11 (+0.03), GILD: 86.55 (+1.08), ACHN: 9.14 (+0.26), AVEO: 0.95 (+0.02), HZNP: 18.71 (+0.52)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TBL Carves New Path with New York License Win

Punching Through to New Opportunities Folks, here's one for the record books: the Team Boxing League (TBL) just nabbed the promoter license from the New York State Athletic Commission, or NYSAC if you're into the alphabet soup. This isn't just paperwork getting shuffled around an office; it's a massive leap forward for team boxing, a sport that steps into the heart of New...

mF International Shuts Down Legacy Business to Focus on BCH

mF International's Bold Digital Leap It’s a big move in the financial landscape when a firm decides to shake things up and pivot hard towards the digital frontier. mF International Limited (NASDAQ:MFI) is shutting the door on its legacy financial trading solutions and dedicating itself entirely to the budding world of digital assets. This isn’t just another facelift;...

Space Cybersecurity: $8.59B Market Opportunity by 2031

Unraveling the Cybersecurity Frontier in Space These days, keeping our tech safe isn't just about stopping your phone from getting hacked or your laptop from being bombarded with spam. We're talking bigger, and I mean cosmos-level bigger. The space cybersecurity scene is ramping up, projected to balloon from $5.52 billion in 2026 to a whopping $8.59 billion by 2031....

Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

LifeSecure Expands with Starscape Agency Launch

LifeSecure's Strategic Move into the Insurance Space LifeSecure Holdings Corporation is planting new roots with its latest venture, Starscape Insurance Agency. This ain't just another splash in the kiddie pool, buddy. This is a big step in bolstering its standing in the insurance sector, focusing sharply on health insurance solutions for individuals, families, and even...

Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Malteurop's Big Bet in China: A Malt Monopoly Move

Malteurop’s Ambitious Leap into China Folks, it looks like Malteurop, the malting arm of the French VIVESCIA Group, is digging its French roots deep into Chinese soil with a move that screams strategy. They’ve just scooped up the Chunlei Malting Co. plant in Jiangsu province, which cranks out enough malt to sling two billion liters of beer annually. Yeah, that's quite...

Amazon OIL9 Drivers Join Teamsters, Demand Better Pay

Amazon's OIL9 Facility Faces Union Uprising Never a dull moment with Amazon, is there? Just when you think you've seen it all in the labor struggle world, drivers at Amazon's OIL9 facility in Merrillville, Indiana, decide to join the Teamsters. These folks are not just making deliveries; they're laying down the battle lines, demanding Amazon acknowledge their union and...

Energy Services Expands with FAMCO Acquisition

Digging Deeper into Energy Services' Next Move Alright, listen up. Today we're diving into Energy Services of America's latest play. They just wrapped up a juicy acquisition, snagging up FAMCO, a utility contractor from West Virginia, for a cool $6.95 million. It's a mix of cold hard cash and some stock from Energy Services' own treasure chest, with a bit put on hold...

Cowfest 2026 Delighted by Frederick's Flying Cows

Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...